Literature DB >> 2788514

Distinct IL-3 activation profile induced by intravenous versus subcutaneous routes of immunization.

R Lelchuk1, M Carrier, L Kahl, F Y Liew.   

Abstract

Lymphoid cells from mice immunized i.v. or s.c. with Leishmania major antigens were analyzed for their capacity to produce lymphokines when stimulated with specific antigens in vitro. Spleen cells from BALB/c mice immunized by the s.c. route produced significantly higher levels of IL-3 and IL-3 mRNA than those from mice immunized by the i.v. route. The differential production of IL-3 was maintained at a wide range of antigen concentrations tested in vitro and for different culturing times. T cell enrichment procedures and treatment with CD4+ mAb in vitro confirmed the T cell nature of the IL-3 producer population. However, the IL-3 production in the two populations of spleen cells was equally high after Con A stimulation in vitro. The IL-2 production by the two populations of cells was also not significantly different after antigen or mitogen stimulation in vitro. To our knowledge, this is the first report of a differential synthesis of IL-3 mRNA and secretion of IL-3 induced by different routes of immunization followed by specific-antigen stimulation in vitro. These findings may also explain earlier observations that i.v. immunization with leishmanial antigen induces protection, whereas s.c. immunization leads to exacerbation of L. major infection, since IL-3 has been previously shown to promote leishmanial infection. The fact that the phenomenon also extends to other antigen systems suggests that this finding may have a broader implication in immune regulation and vaccine development.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788514     DOI: 10.1016/0008-8749(89)90082-8

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  Parenteral insulin suppresses T cell proliferation to islet antigens.

Authors:  Carla J Greenbaum; Marli McCulloch-Olson; Harvey K Chiu; Jerry P Palmer; Barbara Brooks-Worrell
Journal:  Pediatr Diabetes       Date:  2011-05       Impact factor: 4.866

2.  Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis.

Authors:  L P Kahl; R Lelchuk; C A Scott; J Beesley
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

3.  Thymopentin reduces the susceptibility of aged mice to cutaneous leishmaniasis by modulating CD4 T-cell subsets.

Authors:  E Cillari; S Milano; M Dieli; F Arcoleo; R Perego; F Leoni; G Gromo; A Severn; F Y Liew
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

4.  Generation of IL-3-Secreting CD4+ T Cells by Microbial Challenge at Skin and Mucosal Barriers.

Authors:  Shajo Kunnath-Velayudhan; Michael F Goldberg; Neeraj K Saini; Tony W Ng; Pooja Arora; Christopher T Johndrow; Noemi Alejandra Saavedra-Avila; Alison J Johnson; Jiayong Xu; John Kim; Nazanin Khajoueinejad; Christopher D Petro; Betsy C Herold; Gregoire Lauvau; John Chan; William R Jacobs; Steven A Porcelli
Journal:  Immunohorizons       Date:  2019-05-16

5.  ALW peptide ameliorates lupus nephritis in MRL/lpr mice.

Authors:  Huixia Wang; Mei Lu; Siyue Zhai; Kunyi Wu; Lingling Peng; Jie Yang; Yumin Xia
Journal:  Arthritis Res Ther       Date:  2019-12-02       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.